{
    "nctId": "NCT05063643",
    "briefTitle": "Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude",
    "officialTitle": "Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High altitude-a Multicenter, Prospective Cohort Study",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "HER2-positive Breast Cancer, Targeted Therapy, Cardiac Toxicity, High Altitude",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 132,
    "primaryOutcomeMeasure": "Incidence rate of cardiotoxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Histologically confirmed invasive HER2-positive breast cancer.\n2. The baseline left ventricular ejection fraction \\>55%.\n3. Living at high altitude area \uff08\\>2000 meters\uff09for at least 10 years.\n4. ECOG score 0-2.\n5. Expected survival time \u2265 12 months.\n\nExclusion Criteria:\n\n1. Patients with previous breast cancer or other malignant tumor within 5 years.\n2. Patients who had accepted previous anti-HER2 or anthracyclines-based therapy.\n3. Patients with severe heart disease or discomfort.\n4. Patients who are pregnant.\n5. Patients with other conditions considered not suitable to be enrolled by the investigator.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}